Celine Halioua

Doug O'Laughlin, President of SemiAnalysis, delves into OpenAI's ambitious partnerships with major tech players like AMD and the implications for chip supply dynamics. He offers insights into funding AI infrastructure and the evolving landscape of semiconductor investments. Celine Halioua, CEO of Loyal, shares her pioneering work on FDA-directed longevity drugs for dogs, discussing the potential crossovers to human health. She highlights the regulatory advantages of canine trials and the significance of operational excellence in therapeutic development.

Reed Duchscher, Night Media founder scaling creator management; Ankur Goyal, CEO of Braintrust on AI observability; Celine Halioua, Loyal CEO making longevity drugs for dogs; Haseeb Qureshi, Dragonfly partner on crypto meets AI; Spenser Skates, Amplitude CEO who took his analytics firm public; Jon Caramanica, NYT pop critic on viral music. They debate Cournot-style AI dynamics, Micron’s big memory bet, Hollywood vs Seedance 2.0, and viral music mechanics.

Celine Halioua, founder and CEO of Loyal who raised major funding to pursue canine longevity, shares her journey from neuroscience to building drugs that could extend dogs' healthspan. She talks about running a massive 1,300-dog FDA trial. She explains why dogs are a faster path than humans, the portfolio strategy of multiple drug programs, and the challenge of changing investor pattern-matching.

Celine Halioua, Founder and CEO of Loyal, is revolutionizing pet health with her innovative approach to dog longevity. She shares insights from her groundbreaking clinical trial involving 1,300 dogs aimed at creating a pill that could extend canine lifespans by at least a year. Celine discusses why testing longevity drugs on dogs is advantageous for regulatory approval and the potential to translate findings to humans. With a candid critique of Silicon Valley culture and future aspirations, she brings a pragmatic vision to the longevity biotech landscape.

Celine Halioua, CEO and founder of Loyal, explores groundbreaking ways to extend dog lifespans through innovative drug developments. With her background in neuroscience, she discusses the benefits of canine-specific medications and the parallels between dog and human aging. The episode delves into the challenges of developing effective treatments while addressing genetic issues stemming from selective breeding. Celine also shares insights on the ethics of veterinary research and the critical role of continued advancements in pet health for overall well-being.

Celine Halioua, founder and CEO of Loyal and biotech leader building FDA‑approved lifespan drugs for dogs, explains why dogs are the fastest path to human longevity therapeutics. She discusses milestone-based fundraising, recent regulatory wins, the logistics of running large clinical trials, and plans to scale manufacturing and commercial channels.

Celine Halioua, founder and CEO of Loyal, who raised a $100M Series C to develop pet longevity drugs. She outlines Loyal's 10-year plan to move from dogs into cats and humans. She explains why pharma ignored aging, why dogs mirror human aging better than mice, and how dog-first drugs lower cost and speed translation to human therapies.

Celine Halioua, CEO of Loyal, discusses developing longevity drugs for dogs and potentially humans. Topics include FDA approval process, differences between biotech and software startups, mistakes as a founder, growth rate in hiring, and starting with dogs for drug development.

Celine Halioua, CEO and founder of Loyal, is on a mission to extend the lives of our furry companions with groundbreaking biopharmaceuticals. The discussion dives into her innovative drug, LOY-1, which slows aging in large dog breeds and hints at possible benefits for humans. Celine shares insights on the intriguing link between dog size and lifespan, along with the ethical dynamics of life extension. Plus, she sheds light on the unique challenges her biotech company faces in the pet health market.

Celine Halioua, Founder/CEO of Loyal, announced FDA approval for a drug that can extend lifespan, a groundbreaking milestone in longevity biotech. The podcast explores the pursuit of immortality, targeting root causes of aging, challenges in aging research, and a young female founder's experience in the biotech industry.